Joyce Baard is a consultant urologist in the Academic Medical Center (AMC) in Amsterdam. Her medical degree was completed at the University of Groningen, the Netherlands.
Her main fields of interests are the Endourologic treatment of stones, BPE and urothelium tumors of lower and upper tract. Regarding the last she is especially focused on new imaging and diagnostic techniques in close cooperation with the Bio Medical Engineering department of the AMC.
She has an active participation in the Endourology Masterclasses organised by the AMC and the eGrandRounds organised by the Société Internationale d’Urologie (SIU).
She is a member of various urological societies including the Société d’Urologie, European Association of Urology, Endourological Society and the American Urological Association.
Ola Bratt is a consultant urological surgeon and associate professor of urology at Sahlgrenska University Hospital, Gothenburg, Sweden. He has since the 1990s focused on the management of prostate cancer, clinically as well as in his research. He has published more than 100 papers on prostate cancer, including several recent papers on MRI based diagnostics. Until May 2017 he was a member of the Prostate Cancer Team at Cambridge University Hospital in the UK, where mpMRI has since many years been part of the standard prostate cancer diagnostic pathway. Ola Bratt is the principal investigator of the multicentre, randomised active surveillance study SAMS and a member of the steering committee of the international, randomised SPCG-17 study of standardised treatment triggers for men on MRI based active surveillance.
Date and place of birth: Carpi (Modena) Italy 29/4/1951
23/7/76: Graduated in Medicine and Surgery
9/76 – 3/78: Assistant urologist AUSL Modena
1/3/78- 30.4.79: Assistant urologist at S. Maria Nuova hospital (Reggio Emilia)
1978: Visiting dept. of urology Salpetriere University, Paris (1 Month)
30/4/79: Assistant urologist at Ramazzini Hospital USL of Modena
30/6/80: Speciality in Urology
1980: Researcher at the Columbia University Medical Center New York (USA)
1981: Researcher at the University of Florida (Jackson Memorial Hospital of Miami Prof. Politano)
1982: Researcher at the University of San Diego (Prof. Smidt)
1983: Speciality in Oncology at Modena University
1984: Fellow in Oncology at the University of Memphis (Prof. Mark Soloway)
10/85: Board in Urology and Pediatric Urology
86/89: Fellow in Oncology and research at the University of Memphis (basic and clinical research)
10/88: Speciality in General Surgery and position of Attending Urologist at USL of Modena
10/97: Teaching Professor of Urology at the University of Sassari
16/11/98 to March 2000: Position in Urology at HS Raffaele Institute Milan
81/ Present: Member of the EORTC (European Organization for Research and Treatment of Cancer). He was EORTC National Coordinator for Italy (10 years), Chairman Quality control (4 years), Chairman of the superficial bladder cancer subcommittee (4 years)
March 2000 - present: Chairman Dept. Of Urology Estense S. Agostino Hospitl Modena
From june 2000 to 2005: Chairman also dept of Urology B-Ramazzini Hospital Carpi.
In the same period he coordinated urology in the hospitals of Modena, Carpi, Finale E., Castelfranco Emilia, Vignola and Pavullo.
June 2000 present: Teaching Professor of Urology for Geriatrics at the University of Modena
October 2001/2003: Member bladder cancer committee-Seug
December 2001-2010: Member European Society of Uro-oncology (ESOU) board
March 2004-present: Teaching Professor of uro-oncology at the university of Torino and Piemonte Orientale (Novara)
From 2001/2003: Coordinator and teacher of 3 courses of urology at the Columbia University (New York)
January 2005: Organizer II meeting of ESOU (European Society of Oncological – urology) in Bologna
December 2005/2013 Executive Member of SPO (Strategy Planning Office) EAU
September 2010/ Present: Chairman Elected European Society of Urological-Oncology (ESOU)
January 2010 /present: Chairman Bladder Cancer Group of Italian Society of Urology (SIU)
Prof. Brausi published more than 300 articles in peer journals and cooperate in writing 7 books on oncology-urology (5 on bladder cancer and 2 in prostate cancer).
He is the author of 7 videos on “New technologies anddevelopment in surgical approaches” presented at the EAU 2001 (partial nephrectomy in giant angiomyolipoma),at the European Society of Oncologic-Urology (ESOU 2006) : Radiofrequency ablation (RITA) of small renal tumors, at ESOU 2005 (Prostate sparing Radical Cystectomy), at ESOU
2007: Extended lymphadenectomy for muscle invasive TCC of upper urinary tract, at ESOU 2008: Anatomical, mininvasive Radical Cystectomy: The Modena Technique, AT The International meeting on focal therapy 2009 :Electroporation: a novel technique for the focal treatment of localised prostate Cancer (EAU 2011) and Cellvitio for the Diagnosis of Bladder Cancer EAU (2013).
He was visiting Professor at the University of Aachen (1989), Vienna (1998), Milan (2000).
He is member of the AUA, EAU, ESOU, SIU (International Society of Urology), SIU (Italian Society of Urology) SUNI and CLURON, SPO.
He won 6 awards for best poster presentation at the EAU Congress (Birmingham, Vienna, Milan).
He was invited as visiting Professor performing live surgery at the dept. of urology in Bolzano, at the University of Athens, University of Bruxelles, University of Milan.
April 2008/ present: Regional Coordinator of SIURO (Italian Society of Uro-Oncology)
September 2009/ Present elected professor of Urology for the European School of Urology (ESU). Professor Brausi held courses in Romania (Bucarest), Russia (Novodgorov), Uzbekistan (Tashkent).
In January 2011 he was Chairman of the ESOU meeting in London
In June 2011 chaired a Course for European School of Urology (ESU) as Chairman in Slovenia.
In February 2012 he was visiting professor at the dept. of urology of Fundation Puigvert of Barcelona (prof J Palou) doing live surgery: Minivasive Radical Cystectomy and giving lectures on Non Muscle Invasive Bladder Cancer.
February 2012 he was visiting professor at the University of Prague (Prof. M Babjuk): he gave a lecture on radical cystectomy in elderly patients.
May 9.2012: visiting professor at the University of Aachen (Germany) performing live surgery : Extended pelvic lymphadenectomy in recurrent adenocarcinoma of the prostate after radical prostatectomy. In this occasion he gave a lecture on “ The actual treatment of NMIBC”.
May 2012: Board member of Wuof (World Uro-Oncology Federation )
January 2013 Organizer and Chairman of the 10th ESOU meeting in Rome
I undersign, authorize the processing of my personal data hereby transmitted in compliance with italian act N 196 2003.
Jean-Michel Correas is Professor of Radiology at the Paris-Descartes University and is vice-chairman of the Department of Adult Radiology in Necker University Hospital, Paris, France. He got an MD PhD degree from the University of Tours under the supervision of Pr Léandre Pourcelot. He spent almost two years in the USA as part of his PhD participating to the pre clinical and clinical research programs in a small company developing contrast agents for ultrasound. He was Visiting Professor of Radiology at the University of Toronto department of Imaging Research, where he was in charge of several research projects on Ultrasound Contrast Agents under Pr PN Burns supervision, as part of his doctorate of science on Ultrasound Contrast Agents. He was deeply involved in the development of interventional uroradiology. After ablation of more than 80 hepatocellular carcinomas, he developed together with the Adult Urology department the minimally invasive treatment of renal tumors, starting in 2004. He performed more than 400 ablative procedures of renal masses.
Pr Correas is a member of the French Society of Radiology, the French Society of Uroradiology and the European Society of Radiology. He was elected President of the French Society of Ultrasound in 2008.
Hans Crezee received his MSc in Experimental Physics in 1986 (Free University Amsterdam) and his PhD in 1993 (University of Utrecht). His PhD work involved theoretical and experimental verification of thermal models used in hyperthermia treatment planning, with emphasis on the role of blood flow on heat transport. Between 1992 and 1997, he worked on the development of a clinical system for application of interstitial hyperthermia, and from 1997 to 1999 on the clinical application of this system for brain and prostate implants.
Since 2000 he is working at the Department of Radiation Oncology of the Academic Medical Center in Amsterdam on clinical hyperthermia. Since 2008 he is Principal Investigator for the hyperthermia research with a focus on development of new hyperthermia techniques and on the clinical implementation of Hyperthermia and of Hyperthermia Treatment Planning. He has been or currently is project leader for eight research projects supported by the Dutch Cancer Society KWF. Technical innovation included development of a new 8 antenna AMC-8 hyperthermia system for patients with deep seated pelvic tumours (cervix uteri, bladder) which will be commercially available in the near future. Sophisticated Hyperthermia Treatment Planning software has been developed incorporating blood flow and powerful optimisation tools. Past and current clinical hyperthermia research includes feasibility studies and randomised trials applying hyperthermia in cervical cancer, oesophageal cancer, breast cancer and bladder cancer. He is also involved with pre-clinical research on the fundamental mechanism of hyperthermia.
Date & place of birth: June 18, 1981 - Renswoude, the Netherlands - Nationality: Dutch / Nederlandse
Education: 2007 / 2013 (expected): Doctor of Philosophy, Faculty of Medicine, University of Amsterdam, Department of Biomedical Engineering & Physics
2007 / 2012: Master of Science, Medical Biochemistry & Molecular Biology, University of Amsterdam, Swammerdam Institute for Life sciences
2003 / 2007: Bachelor of Science, Life Sciences, Hogeschool Utrecht, Institute of Life Sciences & Chemistry, Major: Molecular Biology, Molecular Diagnostics, Graduation date: June 2007
2003 / 2004: Propaedeutic exam in Life Sciences & Chemistry, University of Professional Education Utrecht, Institute for Life Sciences & Chemistry
1997 / 2002: Undergraduate studies in Physics, Photonics and Photography, differentiation Optotechnology, Technisch College Ede, Major: Optics, Laser Technology and Machine Vision, Minor: Technical Photography, Research Photography, Graduation date: January 2002
May 2011 / Present: Clinical Postdoctoral Fellow, Department of Urology, Department of Biomedical Engineering & Physics, Academic Medical Center / University of Amsterdam
April 2007 / May 2011 PhD. Student, AMC / UvA Bio-Medical Engineering & Physics, Academic Medical Center / University of Amsterdam
April 2006 / April 2007: Research Fellow, Harvard Medical School, Wellman Center for Photomedicine, Massachusetts General Hospital
January 2002 / April 2006: Technician / Lab assistant, AMC / UvA Lasercenter, Academic Medical Center / University of Amsterdam
September 2001 / January 2002: Final Traineeship, AMC / UvA Lasercenter, Academic Medical Center / University of Amsterdam
September 1999 / January 2000: Trainee ship, Fiber Optics Division, AMP / Tyco Electronics
From 2007 until 2011, D.M. de Bruin worked as a Ph.D. student at the department of biomedical engineering & physics (BMEP) at the Academic Medical Center (AMC). As from 2011, he is also employed by the department of Urology of the AMC. Most projects revolve around optical coherence tomography (OCT), a new clinical imaging modality which enables minimal invasive optical biopsy.
D.M. de Bruin co-authored over 20 publications and numerous presentations at scientific conferences since 2007.
Professor Jean de la Rosette qualified in medicine from the University of Nijmegen, the Netherlands, in 1992. He was then appointed consultant urologist and Director Minimal Invasive Urology at the Department of Urology at the University Hospital at Nijmegen. In 1994 he obtained his doctorate. Since 2002 Jean de la Rosette is Professor and Chairman of the Department of Urology at the Academic Medical Centre (AMC) and University of Amsterdam, the Netherlands.
Professor de la Rosette is a member of the Minimal Invasive Treatment of benign prostatic hyperplasia (BPH) committee of the International Consultation on BPH and the chairman of the Renal Stone committee, patronised by the World Health Organisation (WHO). He is past chairman of the EAU Section of Uro-Technology (ESUT) and past chairman of the European Association of Urology (EAU) working party on BPH guidelines. He is appointed as chairman of the Clinical Research Office of the Endourological Society (CROES) and member of the Board of the Endourological Society. He is the past president of the WCE 2005 meeting and scientific chairman of the WCE 2012 meeting. He is at present a member of the Executive Board of the Société International d’Urologie (SIU).
Professor de la Rosette is a member of various urological societies including the American Urological Association (AUA), the European Association of Urology (EAU), the Endourological Society and the Société International d’Urologie (SIU). He is also on the editorial board of the Journal of Endourology, European Urology, Journal of Urology, BJU International, Journal of Central Europe, and Turkish Journal of Urology.
Professor de la Rosette has published over 450 peer-reviewed articles in the field of urology with special focus on minimally invasive therapy, oncological urology and endourology. He co-authors 4 books and has published over 100 book-chapters.
Theo M. de Reijke performed his medical training at the VU University Amsterdam and has worked as an urologist at the Academic Medical Center in Amsterdam since 1987. In 2004 he successfully defended his thesis on immunotherapy for bladder cancer. He has authored more than 150 publications in peer-reviewed journals and contributed to many book chapters. Uro-oncology (bladder and prostate cancer) is his main field of interest. He has been an active member of the European Organization for Research and Treatment of Cancer Genito-Urinary Group for many years and was elected secretary and later chairman until June 2009. In the Netherlands he is chairman of the prostate cancer guideline committee and a member of the bladder cancer guideline committee. He has been chairman of the Dutch urologic training program for residents and a member of the European Board of Urology examination committee. He is an honorary member of the Polish and Romanian Society of Urology. He was elected as visiting professor for the medical school in Warsaw, Poland in 2010.
Current affiliation: Servicio de Urología. Fundación I.V.O.
Short bio-note Dr. José Luís Domínguez-Escrig graduated in Medicine and Surgery in July1994, in Valencia, Spain, continuing his postgraduate training in the UK. Having completed his BST obtained the Membership of the Royal College of Surgeons of England in 2001 and the Fellowship of the Royal College of Surgeons in Urology, FRSC(Urol) in 2009.
From 2004 to 2006 he performed his research at the prestigious Northern Institute for Cancer Research-Newcastle University, UK. On completion of his research project, he submitted the Thesis “Tyrosine Kinase and Farnesyltarnsferase Inhibitors: Potential Selective Tailored Therapeutics in Bladder Cancer” and was awarded the Degree of Doctor of Medicine in 2006.
He has published in several international peer reviewed Journals and he has reviewed articles for BJU Int, Urol Oncology and the Journal of Urology and has imparted several lectures and presented at international meetings including AACR, AUA, EAU, BAUS and AEU.
He returned to Spain in 2011 and he is currently working as a Consultant Urology Surgeon at the Fundación Instituto Valenciano de Oncología (I.V.O.) in Valencia, where he combines his clinical work with an active involvement in translational research, participating as PI in several Clinical Trials in prostate and bladder cancer. Since 2015 is a systematic reviewer for the EAU NMIBC Guidelines panel and also Spanish delegate to the European Board of Urology (E.B.U.) as well as, member of the F.E.B.U. examination committee.
His main interests are urothelial carcinoma NMIBC and MIBC and the evaluation and development of focal therapies in Uro-oncology.
Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands
Dr. Rachel Giles' lab focusses on inherited cystic renal diseases, including nephronophthisis and familial renal cell carcinoma syndromes. We specialize in functional testing of variant disease-associated alleles, using in vitro, ex vivo (renal explant or organoid), and in vivo (zebrafish) models. In addition to her research, Dr. Giles chairs national (Dutch VHL Organization) and international (www.ikcc.org) kidney patient groups.
Associate Professor of Urology
Department of Surgical Sciences
University of Studies of Torino
Paolo Gontero is Associate Professor of Urology at the University of Studies of Torino, Division of Urology, San Giovanni Battista Hospital, Torino, Italy.
He is currently Director of a Second Level Master Degree Course in Prostate Oncology at the University of Torino. His main clinical interests are Oncology Urology Surgery, Laparoscopic and Robotic kidney and prostate oncological surgery and Reconstructive Urology. He has authored and co-authored more than 150 publications on international journals.
His main research interests pertains the development of new treatment modalities for non-muscle invasive bladder cancer and prostate cancer. He is Scientific Director of the “Torino Prostate Project”, a multidisciplinary clinical and research working group in the field of prostate cancer. He is involved in international trials and working groups on the development of new diagnostic and therapeutic modalities for prostate cancer and on the assessment of surgery in high risk prostate cancer.
He is chairmen of the Course on Small Renal Masses at the European School of Urology and holds active membership with EORTC-GU, ISSECAM-EMPACT and eGUS. He has co-authored several book chapters and edited several books, including the latest Problem Based Urology, Springer 2013, awarded by the BMA Book Award as highly commended n surgical specialties.
Selcuk Guven received his medical degree from Erciyes University Medical Faculty in 1998. He was awarded his specialist certification in Urology from Selcuk University Meram Medical School (Director Prof. Kilinc) in 2005, where he served as a clinical instructor and subsequently Assistant Professor. As a visiting scholar, he gained experience in andrology earlier with Prof. Kadioglu. From 2007-2008, he worked on laparoscopy training and joined the Turkish Urological Laparoscopy Group (Turkurolap). Over a period of 4 months in 2008-2009, he completed the fellowship training program in laparoscopy at Klinikum Heilbronn Teaching Hospital under the surveillance of Prof. Rassweiler. He was involved with the CROES Project in 2010 and consulted with Prof. de la Rosette and Prof. Laguna in the Academic Medical Centre as a clinical fellow in laparoscopy and endourology. He became Associate Professor in 2012. He served as an organizing committee member and trainer in national and international urology courses and symposia. Dr. Guven participated as a live surgeon in the symposia and one-to-one training meeting organized by Turkurolap and the Turkish Endourology Society. He has published more than 50 peer-reviewed manuscripts (h-index 14) and numerous book articles, abstracts and conference presentations. His publications have received 955 citations so far. He has served as an Editorial Board Member of European Medical Journal Urology since 2014 and was appointed as an Associate Editor of The New Journal of Urology in 2016 and Endourology Bulletin of Turkish Endourological Society in 2017. He is at present a member of the Turkish Endourological Society Board of Directors and the Joint Turkish Board of Urology. Dr Guven, with his prime interest in minimally invasive management of urinary tract stone disease and endourology, is currently working in the Urology Department of Istanbul Medipol University.
University Professor (University of Lόbeck / Germany)
Senator honoris causa (University of Szeged / Hungary
Education 1971 -1977 University Medical School of Szeged, Hungary
Workplaces and positions
Oktober 1977 - Pharmaceutical Research Inst.
March 1978 Budapest, scientific assistant, CNS-team
1978-1989 Municipal Inst. of Radiation Oncology, Budapest/Hungary
1989-1991 Westfδlische Wilhelms University, Clinic for Radiotherapy (Radiooncology), Mόnster, FRG guest scientist of the Alexander von Humboldt Foundation
1991-1999 Christian Albrechts University of Kiel, Clinic for Radiation Therapy (Radiooncology), Kiel,
1991 - 1992 senior lecturer
1991 - 2005 vice chairman
1992 - 2005 full professor in radiotherapy
1999- 2005 Head of the Interdisciplinary Centre of Brachytherapy of the University Hospital S-H Campus Kiel
2005- at the present Full Professor in Radiotherapy at University of Luebeck, Head of Interdisciplinary Brachytherapy Unit, University Hospital S-H
2008 April Visiting Professor at Yale University Dept. of Otolaryngology, New Haven, USA
I. Price of the Hungarian Scientific Competition of Medical Students (TDK, 1973)
Special Price of the Minister for Education on the Hungarian Scientific Competition of Medical Students (TDK, 1974)
I. Price of the Hungarian Scientific Competition of Medical Students (TDK, 1975)
III. Price of the Hungarian Society of Oncology (1986)
ESTRO "Best Poster Award“ (1991),
Strebel-Medal of the German, Austrian and Swiss Radiotherapy Societies (DEGRO-ΦGRO-SASRO) for life-long excellent clinical brachytherapy activity (2003)
Iris Fischer Memorial Lecture, Yale University/U.S.A. (2009)
Samir Desai Oration Lecture, Indian Brachytherapy Society, Mumbai (2014)
Elis Berven Lecture Award, Swedish Society of Oncology, Oerebro (2017)
Top Physician of Germany (2014, 2015, 2016, 2017)
German Society of Radiotherapy (DEGRO) Founding Member
German Brachytherapy Working Group Founding Chairman (1996-2006)
European Society for Therapeutic Radiology and Oncology (ESTRO)
Hungarian Society of Radiation Oncology
American Society of Radiation Oncology (ASTRO 1995 - 2010)
GEC-ESTRO Council member, Executive Group Member (1991- present), Chairman-elect (2006-2008), Chairman (2008-2010), Past-Chairman (2010 - 2012), Leader of H&N WG (2010-present), Head of the Breast WG subgroup: Target definition following oncoplastic surgery (2011- present), Education & teaching Committee Board Member (2008-present), ACROP GEC Delegate (2013- present)
ESTRO-APAC Executive Board Member (2016 - present)
Hungarian Society of Radiation Oncology (2010)
Belgian Association of Radiation Oncology (2011)
Senator honoris causa - University of Szeged/Hungary (2014)
Dr. M.P. Laguna is a staff member at the department of Urology at the AMC University Hospital. She is responsible for the research at the department and the education of the residents.
Dr. Pilar Laguna has finished her training as urologist in 1982 at the University of Barcelona. She was a staff member of several hospitals in Spain like for example the famous Fundacion Puigvert. She moved to the Netherlands and became a staff member in Nijmegen in 2000. Later on she moved to the capitol city Amsterdam where she became a staff member at the AMC University hospital. In 2003 Dr. Laguna obtained her PhD cum laude at the University of Las Palmas de Gran Canaria.
After a short training in laparoscopy in Brussels she chairs the laparoscopy activities in Amsterdam. She has been assigned an EBM-fellowship and she also is in charge of the practical training in the animal lab for the residents. Her main fields of interest are renal cell cancer, nephron sparing surgery, laparoscopic surgery, cryosurgery and testis cancer.
Dr. Laguna is member of the European Germ Cell Cancer Consensus Group, which determines the guidelines for cancer of the testis. In addition she is a member of the American Urological Society, the Societe International d’Urologie, European Association of Urology and the Endourological Society.
Dr. Laguna has published more than 150 articles and is author of several book chapters.
Christophe Koenraad Mannaerts was born in Jakarta, Indonesia on February 24th, 1991. After finishing pre-university education in 2009 with honors at Lyceum de Grundel in Hengelo, The Netherlands, he continued with medical school at the Radboud University of Nijmegen, The Netherlands. In 2016, he obtained his medical degree with honors after a urology senior internship and a scientific internship on prostate carcinoma at the Radboud University Medical Centre. In July 2016, he started a collaborative PhD research project with the departments of Urology and Electrical Engineering of the University of Amsterdam and Eindhoven University of Technology, respectively. This project is part of the Dutch Cancer Society project granted to prof. dr. ir. H. Wijkstra, titled "Improved prostate cancer detection and localization by contrast enhanced dispersion imaging." Under the supervision of prof. dr. ir. H. Wijkstra and prof. dr. J.J.M.C.H. de la Rosette, he is currently working on multiple studies on prostate cancer diagnosis and treatment. Improving the prostate cancer diagnosis pathway by means of a critical appraisal of current approaches and new imaging and biopsy developments is at the core of his current research.
Translating advanced ultrasound techniques like multiparametric ultrasound, consisting of software based quantification of contrast-enhanced ultrasound and ultrasound shear wave elastography, into clinical prostate cancer practice and comparing imaging-targeted prostate biopsies of contrastenhanced ultrasound and multiparametric magnetic resonance imaging with systematic biopsies are an example of his research work. Moreover, he is involved in research on novel maging modalities including confocallaser endomicroscopy and optical coherence tomography, and focal therapy for localized prostate cancer with irreversible electroporation. His work will be presented in a dissertation of which some have already been published in peer reviewed journals and presented at national and international urological congresses and meetings.
Urologic Oncology Branch
National Cancer Institute
National Institutes of Health
Department of Health and Human Services
10 Center Drive MSC 1210
Building 10, CRC, Room 2W-5940
Bethesda, Maryland 20892-1210
Fellow– Minimally Invasive Surgery and Oncology
James Buchanan Brady Urological Institute
Johns Hopkins Medical Institutions
Administrative Chief Resident
Department of Urology
Long Island Jewish Medical Center
New Hyde Park, New York
Department of Urology
Long Island Jewish Medical Center
New Hyde Park, New York
Department of General Surgery
Long Island Jewish Medical Center
New Hyde Park, New York
Medical Education State University of New York
Health Science Center at Syracuse- Syracuse, New York
Fordham University- Bronx, New York
Honors and Awards
NIH Bench to Bedside Research Grant – 2010
Optical guidance for improved prostate cancer surgery.
$135,000 over 2 years
NIH Bench to Bedside Research Grant – 2004
Infrared and Near Infrared Image Guided Minimally Invasive Assessment of Renal
Perfusion during Donor Nephrectomies and Partial Nephrectomies for Renal Cell Cancer. $130,000 over 2 years.
Johns Hopkins -Brady Urological Institute Teaching Award – 2003
Nagamatsu Fellow (Society of Urology and Engineering) – 2001
Patents Novel Surgical Trocar for Light and Laser Emittance (NIH # E-095-2006) - provisional NIH patent pending System and method for prostate cancer detection and distribution mapping - provisional NIH / Philips Corporation patent pending
National Cancer Institute, Center for Cancer Research Clinical Review Panel
This panel conducts yearly quadrennial reviews of CCR Staff Clinicians. (2010 - present).
Surgical Neurology Branch Search Committee for an Assistant Clinical Investigator in the National Cancer Institute, Center for Cancer Research 2010
National Cancer Institute Cancer Advisory Board (2009-present)
NIH Clinical Research Training Program (CRTP) Fellowship Committee (2007-present)
Society of Urologic Oncology Fellowship Committee (2005-present)
American Urologic Association Education Task Force (2005-present)
Surgical Action Committee, National Cancer Institute, NIH (2003-present)
Intensive Care Unit / Critical Care Partners Meeting, NIH(2003-present)
Surgical Oncology Unit Partners Meeting, NIH (2003-present)
• The Canadian Journal of Urology (Editorial Board)
• The Cancer Journal
• The Journal of Urology
• American Journal of Transplantation
• Journal of Endourology
• International Journal of Computer Assisted Radiology and Surgery
Clinical Research Training Program (CRTP) medical student Mehrdad Alemozaffar from UCLA (July 2005-July 2006)
Investigated the role of molecular targeted therapies (17-AAG, a heat shock protein inhibitor) in the treatment of prostate cancer
Matched in urology residency at Harvard University, Brigham and Women’s Hospital
Clinical Research Training Program (CRTP) medical student Jack Liu from UCLA (July 2006- July 2007)
Investigated the role of spectral analysis in the differentiation of normal and cancerous renal tissue.
Matched in otolaryngology residency at UCSF
Clinical Research Training Program (CRTP) medical students Kiranpreet Khurana from UMDNJ (July 2007- July 2008)
Investigating the role of image guidance and magnetic resonance ultrasound fusion in the diagnosis and treatment of prostate cancer.
Matched in urology residency at Cleveland Clinic, Glickman Urological and Kidney Institute
Nick Liu from Georgetown (July 2007- July 2008) matched in urology residency at Indiana University
Clinical Research Training Program (CRTP) medical student Deborah Kaye from Medical College of Wisconsin (July 2008- July 2009)
Studying the potential application of Met, a proto-oncogene, as a biomarker for prostate cancer.
Matched in urology residency at Johns Hopkins, Brady Urological Institute Thomas Sanford from Hawaii (July 2008- July 2009) matched in urology residency at UCSF
Clinical and research training for urology residents from Georgetown – Washington Hospital Center Medical Center and George Washington Medical Center
40th CAnnual Washington Urologic Society Resident Scholars Day 2nd place research prize for “Feasibility and Outcomes of Repeat Partial Nephrectomy” Aaron Johnson, MD
41st Annual Washington Urologic Society Resident Scholars Day 1st place research prize for “Immunomodulary Management of Superficial Bladder Cancer with IL-12 and Chitosan in a Murine Model” Compton Benjamin, MD, PhD
Clinical and research training for 2 year SUO accredited urologic oncology fellows
Licensure and Certifications • Diplomate, American Board of Urology
• Basic Life Support
• Advanced Cardiac Life Support
• Pediatric Advanced Life Support
• New York State Medical License
• Maryland State Medical License
Society Memberships • Phi Beta Kappa
• Sigma Xi
• American Urological Association
• Mid-Atlantic Section of the AUA
• Society of Urologic Oncology
• American Medical Association
• Society of Urology and Engineering
• Endourology Society
• American Association of Clinical Urologists
1985-86 Honour School of Physiological Sciences, Worcester College, Oxford University, England (Psychology)
1983-87 Georgetown University, Washington, DC (Biology)
1987-91 Pritzker School of Medicine, University of Chicago, Chicago, IL (Medicine, MD)
1991-97 Johns Hopkins Medical Institutions – Urology residency, fellowship and faculty (Urology)
• 1997-98 | Assistant Chief of Service, Instructor in Urology, James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, MD
• 1998-2003 | Assistant Professor of Surgery, Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC
• 2003 -2009 | Associate Professor (with tenure, 2009-2011)
• 2011-present | Professor of Urology with tenure
• 2007-present | Director of Urologic Oncology program
• 2012-present | Director of Genitourinary Focal Therapy program
Editorial, advisory board, academic and societal positions
• 1998-present Ad hoc reviewer: Urology, Lancet Oncology, Cancer, European Urology, Journal of Urology, BJU International, Urologic Oncology, Technology in Cancer Research and Treatment, Nature Clinical Practice Urology, etc
• 1998- 2005 Medical Director, Duke Community Urology, Duke University, Durham NC
• 2001 Advisory Board, NCI-funded Fresh Start Project on "Promoting Health in Prostate and Breast Cancer Survivors”
• 2002-2005 Medical Director, Duke Comprehensive Cancer Center Prostate Cancer Screening
• 2003-04 Leadership College of the North Carolina Medical Society
• 2004-06 Secretary of the North Carolina Urological Association
• 2005-2011 Board of Directors, Southeastern Section of the American Urological Association
• 2006-07 Vice President, North Carolina Urological Association
• 2007-2009 President, North Carolina Urological Association
• 2007-13 Southeastern Section of the American Urological Association Health Policy Council – North Carolina representative
• 2008-10 Coordinating Council of Specialty Societies of the North Carolina Medical Society – Urology representative
• 2007+ European Organisation for Research and Treatment of Cancer (EORTC) – Independent Data Monitoring Committee (IDMC) – external reviewer
• 2008-11 Representative of North Carolina, Southeastern Section of the American Urological Association Board of Directors
Current Funded Projects
• Construction of a renal mass database and tissue repository. Department Fund, $38,000, 2011-12.
• FEM-based Acoustic Radiation Impulse Imaging and MR Image Registration for Focal Prostate Cancer Procedures. Coulter Foundation award 383-4328, 5% effort, 2012-13.
• Acoustic Radiation Force Impulse imaging of in-vivo prostate cancer prior to prostatectomy. NIH 1R-01 CA142824-01, 2009- present
Selected Bibliography (from total 203 peer-reviewed publications)
• Mouraviev V, Sun L., Mayes JM, Madden JF, Moul JW, and Polascik TJ. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology. 2007; 70:1141-1145.
• Mouraviev V, Nosnik I, Robertson C, Albala D, Walther P and Polascik TJ: Comparative financial analysis of minimally invasive surgery to open surgery for small renal tumours < 3.5 cm: A single institutional experience. European Urology 51:715-721, 2007.
• Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, Fitzsimons N, Albala D and Polascik TJ: Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU International, 99: 753-757, 2007.
• Mouraviev V, Joniau S, Van Poppel H , and Polascik TJ: Current Status of Minimally Invasive Ablative Techniques in the Treatment of Small Renal Tumours. European Urology 51: 328-336, 2007.
• Polascik TJ and Mouraviev V: The rise of ablative technologies for treating the small renal mass. European Urology 52(3): 636-638, 2007.
• Mouraviev V, Polascik TJ, Mayes J, Sun L., Madden JF, George D, Febbo P., Moul JW. Prostate Cancer Laterality as a Rationale of Focal Ablative Therapy for the Treatment of Clinically Localized Prostate Cancer. Cancer. 2007; 110:906-910.
• Megwalu II, Ferguson GG, Wei JT, Mouraviev V , Polascik TJ, Taneja S, Black L, Andriole GL, Kibel AS. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int.2008; 102(5):546-50.
• Schroeck FR, Krupski TL, Sun L, Albala DM, Price MM, Polascik TJ, Robertson CN, Tewari AK and Moul JW: Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol, 54: 785-793, 2008.
• Polascik TJ , Mayes JM, Sun L, Madden JF, Moul JW, and Mouraviev V: Pathologic Stage T2a and T2b Prostate Cancer in the Recent Prostate-specific Antigen Era: Implications for Unilateral Ablative Therapy. Prostate 68: 1380-1386, 2008.
• Polascik TJ, and Mouraviev V. Focal therapy for prostate cancer. Current Opin Urol: 18:269-74, 2008.
• Schroeck FR, Donatucci CF, Smathers EC, Sun L, Albala DM, Polascik TJ, Moul JW and Krupski TL: Defining potency: A comparison of the International Index of Erectile Function short version (IIEF-5) and the Expanded Prostate Cancer Index Composite (EPIC). Cancer 113(10): 2687-94, 2008.
• Mouraviev V, Mayes JM, and Polascik TJ: Pathologic Basis of Focal Therapy for Early Stage Prostate Cancer. Nature Reviews Urology, 6(4): 205-15, 2009.
• De la Rosette JMCH, Mouraviev V and Polascik TJ: Focal targeted therapy will be a future treatment modality for early stage prostate cancer. Eur Urology, 8: 424-432, 2009
• Chen VH, Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW and Polascik TJ: Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection. Technology in Cancer Research and Treatment:8 (2): 99-104, 2009.
• Polascik TJ, Mayes JM, Schroeck FR, Sun L, Madden JF, Moul JW, and Mouraviev V: Patient Selection for Hemi-ablative Focal Therapy of Prostate Cancer: Variables Predictive of Tumor Unilaterality based upon Radical Prostatectomy. Cancer, 115(10): 2104-10, 2009.
• Mouraviev V, Madden JF, Broadwater G, Mayes JM, Burchette JL, Schneider F, Smith JS, Tsivian M, Wong T and Polascik TJ: Use of 111In-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. J Urol 182: 938-948, 2009.
• Tsivian M, Kimura M, Sun L, Mouraviev V, Mayes JM and Polascik TJ: Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant versus extended. BJU-I, 105(8): 1089-1092, 2010.
• Polascik TJ and Mouraviev V: Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urology 74(4): 726-30, 2009.
• Tsivian M, Mayes JM, Krupsky TL, Mouraviev V, Donatucci CF and Polascik TJ: Altered male physiologic function after surgery for prostate cancer: Couple perspective. International Braz J Urol, 35(6): 673-682, 2009.
• Mayes JM, Mouraviev V, Tsivian M, Krupski TL, Donatucci CF and Polascik TJ: Concordance in the perception of couples recovering from primary surgical treatment of prostate cancer. Int J Impotence Res 21(4): 253-260, 2009.
• Kimura M, Mouraviev V, Tsivian M, Moreira DM, Mayes JM and Polascik TJ: Analysis of urinary function using validated instruments and uroflowmetry after primary and salvage prostate cryoablation. Urology 76(5): 1258-1265, 2010
• Tsivian M, Moreira DM, Sun L, Mouraviev V, Kimura M, Moul JW and Polascik TJ: Biopsy accuracy identifying unilateral prostate cancer depends on prostate weight.Urol Oncol, 30: 21-25, 2012.
• Mouraviev V, Bjerklund-Johansen TE and Polascik TJ: Contemporary results of focal therapy for prostate cancer using cryoablation. J Endourol 24 (5): 827-834, 2010.
• De la Rosette J, Ahmed HU, Barentsz J, Bjerklund-Johansen T, Brausi M, Emberton M, Frauscher F, Greene D, Harisinghani M, Haustermans K, Heidenreich A, Kovacs G, Mason M, Montirone R, Mouraviev V, deReijke T, Raneja S, Taneja S, Thuroff S, Trachtenberg J, Wijkstra H, and Polascik TJ: Focal therapy in prostate cancer – report from a consensus panel. J Endourology, 24(5): 775-780, 2010.
• De la Rosette JJ, Gill I and Polascik TJ: Focal therapy for prostate and renal cancer: are we ready for it? J Endourology, 24(5): 663, 2010.
• Tsivian M, Hruza M, Mouraviev V, Rassweiler J and Polascik TJ: Prostate biopsy in selecting candidates for hemiablative focal therapy. J Endourology 24(5): 849-854, 2010.
• Tsivian M and Polascik TJ: Focal Cryotherapy for prostate cancer. Curr Urol Rep11:147-151, 2010.
• Zhai L, Madden J, Foo WC, Palmeri ML, Mouraviev V, Polascik TJ and Nightingale KR: Acoustic Radiation Force Impulse Imaging of Human Prostates ex vivo. Ultrasound Med Biol 36(4): 576-588, 2010.
• Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ and Brewster S: Focal therapy for prostate cancer: possibilities and limitations. Eur Urol, 58(1): 57-64, 2010.
• Baust JG, Klossner DP, van Buskirk RG, Gage AA, Mouraviev V, Polascik TJ and Baust JM: Integrin involvement in freeze resistance of androgen-insensitive prostate cancer. Prost Cancer Prostatic Dis 13(2): 151-161, 2010.
• Choueiri TK, Chen MH, D’Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW: Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer, 116(8): 1887-92, 2010.
• Zhai L, Madden J, Foo WC, Palmeri ML, Mouraviev V, Polascik TJ and Nightingale KR: Acoustic Radiation Force Impulse Imaging of Human Prostates ex vivo. Ultrasound Med Biol 36(4): 576-588, 2010.
• Kimura M, Rabbani Z, Mouraviev V, Tsivian M, Caso J, Satoh T, Baba S, Vujaskovic Z, Baust JM, Baust JG and Polascik TJ: Role of vitamin D3 as a sensitizer to cryoablation in a murine prostate cancer model: preliminary in vivo study. Urology, 2010 76(3): 764.e14-20.
• Tsivian M, Chen VH, Kim CY, Zilberman DE, Mouraviev V, Nelson RC, Albala DM and Polascik TJ: Complications of laparoscopic and percutaneous renal cryoablation in a single tertiary referral center. Eur Urol 58(1): 142-148, 2010.
• Kimura M, Rabbani Z, Mouraviev V, Tsivian M, Vujaskovic Z, Satoh T, Baba S, Baust JM, Baust JG and Polascik TJ: Morphology of hypoxia following cryoablation in a prostate cancer murine model: its relationship to necrosis, apoptosis and microvessel density. Cryobiology 61(1): 148-154, 2010.
• Zhai L, Madden J, Foo WC, Mouraviev V, Polascik TJ, Palmeri ML and Nightingale KR: Characterizing stiffness of human prostates using acoustic radiation force. Ultrasonic Imaging 32 (4): 201-213, 2010.
• Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R, and Polascik TJ: Understanding the pathological features of focality, grade and tumour volume of early stage prostate cancer as a foundation for parenchyma-sparin prostate cancer therapies:Active surveillance and focal targeted therapy BJUInt.108:1074, 2011.
• Tsivian M and Polascik TJ: The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU Int, 108(3): 371, 2011.
• Mouraviev V, Kimura M, Venkatraman T, Tsivian M, Mouravieva V, Batinic-Haberle I, Polascik TJ, Wang H, and Lascola C: Mn-porphyrins as novel molecular MRI contrast agents. J Endourology,2011 Nov3[Epub ahead of print].
• Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, Hricak H, Kattan MW, Kurhanewicz J, Moore CM, Parker C, Polascik TJ, Scardino P, van As N, and Villers A: Transatlantic Consensus Group on Active Surveillance and Focal Therapy for Prostate Cancer. BJU-I, [epub ahead of print] Nov 11, 2011.
• Santucci KL, Snyder KK, Baust JM, Van Buskirk RG, Mouraviev V, Polascik TJ, Gage AA and Baust JG: Use of 1,25α dihydryoxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. Prost Cancer Prost Dis 14(2): 97-104, 2011.
• Kimura M, Yan H, Rabbani Z, Satoh T, Baba S, Yin FF, Polascik TJ, Donatucci CF, Vujaskovic Z and Koontz BF: Radiation-induced erectile dysfunction using prostate-confined modern radiotherapy in a rat model. J Sex Med 8(8): 2215-26, 2011.
• Tsivian M, Moreira DM, Caso JR, Mouraviev V, and Polascik TJ: Cigarette smoking is associated with advanced renal cell carcinoma. J Clin Oncol, 29(15): 2027-31, 2011.
• Kimura M, Donatucci CF, Tsivian M, Caso JR, Moreira DM, Mouraviev V, Satoh T, Baba S, Polascik TJ: On-demand use of erectile aids in men with preoperative erectile dysfunction treated by whole gland prostate cryoablation. Intl J Impot Res: J Sex Med, 23(2): 49-55, 2011.
• Kimura M, Banez LL, Schroeck FR, Gerber L, Qi J, Satoh T, Baba S, Robertson CN, Walther PJ, Donatucci CF, Moul JW, and Polascik TJ: Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. J Sex Med 8(10): 2935-43, 2011.
• Zhai L, Polascik TJ, Foo WC, Rosenzweig S, Palmeri ML, Madden J and Nightingale KR: Acoustic radiation force impulse imaging of human prostates: initial in vivo demonstration. Ultrasound Med Biol, 38(1): 50-61, 2012.
• Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, Frauscher F, Kovacs G, Matin SF, Mischi M, Pinto P, Rastinehad A, Rouviere O, Salomon G, Polascik T, Walz J, Wijkstra H and Marberger M: Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: Report from a consensus panel. BJU-Int 110(7): 942-8, 2012.
• Abern MR, Tsivian M and Polascik TJ: Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria. Curr Urol Rep 13(2): 160-169, 2012.
• Kimura M, Banez LL, Gerber L, Qi J, Tsivian M, Freedland SJ, Satoh T, Polascik TJ, Baba S and Moul JW: Association between preoperative erectile dysfunction and prostate cancer features – an analysis from the Duke Prostate Center Database. J Sex Med 9(4): 1174-81, 2012.
• Tsivian M, Qi P, Kimura M, Chen VH, Chen SH, Gan TJ and Polascik TJ: The effect of noise-cancelling headphones or music on pain perception and anxiety in men undergoing transrectal prostate biopsy. Urology, 79(1): 32-6, 2012.
• Kimura M, Rabbani ZN, Zodda AR, Yan H, Jackson IL, Polascik TJ, Donatucci CF, Moul JW, Vujaskovic Z and Koontz BF: Role of oxidative stress in a rat model of radiation-induced erectile dysfunction. J Sex Med 9(6): 1535-49, 2012.
• Kimura M, Caso JR, Banez LL, Koontz BF, Gerber L, Senocak C, Donatucci CF, Vujaskovic Z, Moul JW, and Polascik TJ: Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy. BJU Int, 110(11Pt C): E931-8, 2012 Apr 23 [Epub].
• Tsivian M, Abern MR and Polascik TJ: Prostate cancer treatment unblinded. ed comment on: Focal therapy for localized unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol, 13(6): 567-8, 2012
• Kimura M, Banez LL, Polascik TJ, Bernal RM, Gerber L, Robertson CN, Donatucci CF and Moul JW: Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post-operative sexual dysfunction. Andrology 1(2): 256-61, 2013, doi: 10.1111/j.2047-2927.2012.00036.x. Epub 2012 Nov 29. PMID: 23413138
Ardeshir (Art) Rastinehad, D.O. joined the faculty from the National Cancer Institute as an Interventional Urologic Oncologist specializing in the surgical management of prostate, kidney, adrenal, and testicular cancer. He has a faculty appointment in the Department of Radiology and Urology. He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, laparoscopic and robotic surgery.
For three decades, urologists have diagnosed prostate cancer using the same methodologies. There have been no reliable imaging tools to aid in the diagnosis and currently prostate cancer is the only solid malignancy that is still diagnosed by random biopsies.
Dr. Rastinehad’s prostate cancer team has now incorporated state-of-the-art imaging to help visualize suspicious areas in the prostate for cancer. Dr. Rastinehad has also authored and implemented clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. Most recently, he is the principle investigator for a phase III clinical trial using MRI/Ultrasound fusion technology to improve prostate biopsy techniques. Using information from the prostate MRI, we can now target specific areas to better diagnose and quantify a patient’s prostate cancer. This was the first trial of this technology in the United States outside the National Institutes of Health. This new clinical approach is helping to lay a foundation for the evaluation of a new technique, Focal Therapy, which only treats the diseased portion of the prostate. For more information please visit www.interventionalurology.com.
Dr. Rastinehad’s research has been published in leading national and international medical journals including The Journal of Urology, Journal of Radiology, Urology, and The British Journal of Urology. He has also authored several book chapters. Dr. Rastinehad is a leader in his field of Uroradiology and Interventional Urology and has been invited to speak at many international and national meetings. He has also serves as the course director for the first international course on MR US fusion guided prostate biopsies sponsored by the American Urological Association. Dr. Rastinehad is the first urologist to practice interventional urology, which utilizes interventional techniques to treat urologic problems and is currently evaluating prostate embolization as an alternative to transurethral resection of the prostate (TURP).
Research Professor of the French National Institute for Health and Medical Medical Research, Institut Langevin, ESPCI, Paris France
Mickaël Tanter is the director of the Inserm laboratory “Wave Physics for Medicine” and deputy director of Langevin Institute at ESPCI, Paris, France. He is a world renowned expert in biomedical ultrasound and wave physics. He is the author of more than 300 peer-reviewed papers and book chapters and the recipient of 45 international patents. He co-invented several major innovations in Biomedical Ultrasound: Transient Elastography, Ultrafast Ultrasound and Shear Wave Elastography, functional Ultrasound imaging of brain activity and Super-resolution Ultrasound. He received many national and international distinctions (among them the Honored Lecture of the Radiology Society of North America in 2012, the Grand Prize of Medicine and Medical Research of Paris city in 2011 and the Grand Prize of Fondation de la Recherche Médicale in 2016). He was recently awarded a European Research Council (ERC) Advanced Grant to introduce fUltrasound imaging (functional imaging of brain activity) as a new full-fledged neuroimaging modality. M. Tanter is the co-founder of several MedTech companies in Biomedical Ultrasound (Supersonic Imagine, CardiaWave, Neuroflows). In 2006, he co-founded Supersonic Imagine, an innovative French company positioned in the field of medical ultrasound imaging that launched in 2009 a revolutionary Ultrafast Ultrasound imaging platform called AixplorerTM with a unique real time shear wave imaging modality for cancer diagnosis (more than 1700 ultrafast scanners already sold worldwide).
1988-1993 Urology Residency and Fellow, Kyoto Prefectural University of Medicine, Kyoto, Japan
1993-1994 Visiting Assistant Professor, Department of Urology, MD Anderson Cancer Center, University of Texas, Texas, USA
1994-2003 Assistant Professor, Department of Urology, Kyoto Prefectural University of Medicine, Kyoto Japan
2003-2006 Research Scholar, Glickman Urological Institute, The Cleveland Clinic, Ohio, USA
2006-2009 Associate Professor, Department of Urology, Kyoto Prefectural University of Medicine, Kyoto Japan.
2009-2015 Clinical Professor of Urology, University of Southern California, Los Angeles, USA
2015-present Professor and Chairman of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan
2005 | “First Prize”, Best of Best Video, 100th AUA Annual Meeting, San Antonio (Real-time Transrectal Ultrasound Monitoring during Nerve-sparing Laparoscopic Radical Prostatectomy)
2013 | “First Prize Award”, for the Best Video, 28th Annual EAU Congress, Milan
2014 | Co-chairman (with Gill IS) of 7th International Symposium and Imaging and Focal Therapy in Prostate Cancer and Kidney Cancer, Los Angeles
2015 | “Best Poster in Clinical Research of Prostate Cancer”, 8th International Symposium and Imaging and Focal Therapy in Prostate Cancer and Kidney Cancer, Amsterdam
2017 | “Best Scientific Paper Award of European Urology in 2016” (A RCT to assess and compare the outcome of 2-core prostate biopsy guided by fused MR/TRUS images and traditional 12-core systematic biopsy. Eur Urol 2016, 149-156)
Doctor Massimo Valerio qualified in medicine and completed a MD degree at the University of Bari, Italy, in 2006. He terminated his residency in 2012 at the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland. After obtaining a Certificate of Advanced Studies in clinical research in 2011 from the University of Lausanne, he joined the University College London group as research associate, and achieved a PhD in this university in 2016. He is staff member at the Centre Hospitalier Universitaire Vaudois in Lausanne since 2014, and Privat-Docent at the University of Lausanne since 2016.
His research mainly focuses on health technology assessment of minimally invasive technologies in diagnosis, risk stratification and treatment of patients with prostate cancer. His research has been reported in over 50 peer-reviewed publications and presented at international congresses. Dr Valerio is a member of the EAU Young Academic Urologists – Prostate Cancer working group, of the EORTC – genitourinary malignancies group and of the ERAS – urology group. He acts as editorial board member and/or reviewer for over 20 peer-reviewed journals.
Hessel Wijkstra (1955) received the M.Sc. degree in electrical engineering at the Twente University of Technology, Enschede, the Netherlands. He received at the same University the Ph.D. degree with the thesis: ‘The flow pulse response of the ventricular pressure source’. He has been performing bio-medical research in the department of Urology of the Radboud University Hospital, Nijmegen, the Netherlands. Since 2004 he is a faculty member of the department of Urology at the AMC University hospital, Amsterdam, the Netherlands. His main research topic is imaging, in particular contrast enhanced ultrasound, in the diagnosis and treatment of prostate and kidney cancer.
Since November 2010 he is part-time professor at the Eindhoven University of Technology focusing on the clinical validation and implementation of contrast enhanced imaging techniques.